Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.

The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

The conversation discusses using RU58841 for hair loss, with OP experiencing thinning in the front area and steady hair loss. OP plans to try microneedling while avoiding finasteride and dutasteride.

The user has been using finasteride 1mg and minoxidil 5% spray for 19 months but continues to experience hair shedding and has not seen improvement with ketoconazole or tretinoin. They are considering a hair transplant in the future while maintaining current treatments.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

The user experienced almost no improvement in hair loss after 3 months using microneedling, RU58841, sulforaphane, finasteride, and dutasteride, especially after stopping minoxidil. They believe minoxidil is more effective than RU58841.

The user experienced significant hair loss after using RU58841 for a week and is seeking advice on recovery. They previously had side effects from finasteride and dutasteride.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

A user expressed frustration with hair loss treatments, including finasteride, minoxidil with micro-needling, and RU58841, which all failed to stop hair thinning and miniaturization. Suggestions from others included accepting baldness, considering hair systems, and continuing prescribed antidepressants for depression.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.